Omeros' (OMER) Buy Rating Reiterated by D. Boral Capital

On January 19, 2025, D. Boral Capital confirmed their "Buy" rating for the shares of Omeros Corporation (NASDAQ:OMER – Free Report). In their recent report, they set a target price of $36.00 for the biopharmaceutical company's stock.

Recently, several analysts have provided insights regarding Omeros. For instance, StockNews.com upgraded Omeros from a "Sell" rating to a "Hold" rating as per a research report dated November 20th, 2024. On November 14th, Cantor Fitzgerald reiterated a "Neutral" rating for the company's shares. That same day, Rodman & Renshaw began coverage of Omeros, issuing a "Buy" rating accompanied by a price target of $9.00. Needham & Company LLC also maintained a "Hold" rating on Omeros in their research from December 19th, 2024. Conclusively, Rodman & Renshaw elevated Omeros to a "Strong Buy" rating on November 14th. Overall, three analysts have labeled the stock as a hold, while two have assigned it a buy rating, and one has given it a strong buy rating. Current data from MarketBeat.com indicates that the prevailing consensus rating for Omeros is a "Moderate Buy" with an average price target set at $22.50.

Omeros Shares See an Uptick

As of Thursday, shares of NASDAQ:OMER opened at $9.33. The company has a fifty-day moving average of $9.35 and a two-hundred-day moving average price of $6.01. Omeros carries a market capitalization of approximately $540.67 million, with a price-to-earnings ratio of -4.04, and a beta value of 2.01. The company’s stock has experienced a one-year low of $2.61 and a one-year high of $13.60.

Institutional Investors Adjust Holdings

Changes have recently occurred among institutional investors and hedge funds concerning their positions in Omeros. BNP Paribas Financial Markets increased its stake in Omeros by 130.6% during the third quarter, now holding 12,388 shares valued at $49,000 after collecting an additional 7,016 shares. Similarly, MML Investors Services LLC raised its position by 19.2% during the same quarter, accumulating a total of 18,600 shares worth $74,000 following an additional purchase of 3,000 shares. Moreover, SPC Financial Inc. initiated a new holding in Omeros during the third quarter valued at $77,000, while SG Americas Securities LLC also acquired a fresh stake worth $80,000. Additionally, AQR Capital Management LLC invested in Omeros in the second quarter, with a stake valued at approximately $105,000. Currently, institutional investors and hedge funds own around 48.79% of Omeros’ stock.

Overview of Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical firm that specializes in discovering, developing, and commercializing small-molecule and protein therapeutics, particularly those addressing orphan conditions and immunologic diseases. This includes target diseases such as complement-mediated disorders, cancers, and addictive and compulsive disorders. The company is actively developing several products, including Narsoplimab (OMS721/MASP-2), which has concluded its pivotal trial for treating hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) and is currently in a Phase III clinical trial aimed at addressing immunoglobulin A nephropathy (IgAN), as well as a Phase II trial related to COVID-19.

Omeros, Rating, Analysis